H.C. Wainwright raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $27 and keeps a Buy rating on the shares. The firm expects veligrotug to meet the endpoints in chronic thyroid eye given that Tepezza demonstrated efficacy in chronic TED treatment. It thinks veligrotug will show at least comparable efficacy to Tepezza.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN: